Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows

A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing. 

Pricing Strategies Pricing Debate Reimbursement

Latest From Pricing Debate

Interview: EULAR Head Counting The Cost Of Rheumatic Disease

Hans Bijlsma, president of the European League Against Rheumatism, tells Scrip about the progress being made in rheumatic and muskuloskeletal diseases, the areas where more innovation is needed and the importance of early treatment, both clinically and financially.

Immune Disorders Biosimilars

UK Industry Raises Conflict of Interest Concerns Over NICE’s PRIMA Service

PRIMA, the new service the National Institute for Health and Care Excellence offers to review economic models, must not be affected by confidentiality and conflict of interest issues, warns UK the pharmaceutical industry group, ABPI.

Europe United Kingdom

340B Legislative Reforms: Where Do We Go From Here?

Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.

Legislation Pricing Strategies

CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor

The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee.  During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.

Legislation Generic Drugs

Congressional Action On Drug Pricing Blueprint Likely To Be Modest

Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.

Pricing Debate Legislation

Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy

Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.

Pricing Debate Medicare

Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says

Companies responding to inquiries from Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., did not indicate they are planning to reduce list prices, despite promises by President Trump, Warren told a June 12 hearing. 
Pricing Debate Pharmacy Benefit Management

The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant

Those “massive” price cuts US President Trump said would be announced this week? Never mind.
Reimbursement Pricing Debate

Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown

Where can HHS go it alone, and where does it need Congress?
Pricing Debate Policy
See All